Accustem Sciences Inc. ACUT
Set alert
0.13 USD 0.00 0.00%
At close · Oct 30
0.13 Day range 0.15
0.117 52-week range 1.07
- YTD
- -84.02%
- 1 year
- -89.26%
- Open
- 0.15
- Prev close
- 0.13
- Mkt cap
- 2.09M
- Vol
- 4
- Avg vol
- 2.67K
- EPS
- -0.10628
- P/E
- -1.22
More statistics
- Low
- 0.13
- High
- 0.15
1M chart
Signals (8)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 29, 2026 | 4 days ago |
| SMA: Bearish | Oct 29, 2026 | 4 days ago |
| MACD: Sell Signal | Oct 29, 2026 | 4 days ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 26, 2026 | 1 week ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| SMA: Bearish | Oct 20, 2026 | 1 week ago |
News
- AccuStem Sciences Announces StemPrintER Pilot Study with National Surgical Adjuvant Breast and Bowel Project (NSABP)
- AccuStem Sciences and EmeritusDX Expand Blood-Based Testing Capabilities to Advance Cancer Diagnostics and Treatment Planning
- AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
- AccuStem Sciences to Present at the Life Sciences Virtual Investor Forum September 18th
- AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
- AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
- AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening
- AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
- AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan
- AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
Your note
Sign in to keep a note on ACUT — it syncs with the Stock Master app.